Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Syros Pharmaceuticals Inc
SYRS
Healthcare
Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in...
combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SYRS)
New Post
View:
Posts & Comments
Threaded Posts
(280)
•••
whytestocks
X
Post by
whytestocks
on Sep 05, 2024 11:47am
Bronstein, Gewirtz and Grossman, LLC Is Investigating Syros
NEWS: $SYRS Bronstein, Gewirtz and Grossman, LLC Is Investigating Syros Pharmaceuticals, Inc. (SYRS) And Encourages Investors to ConnectNEW YORK CITY, NY / ACCESSWIRE / September 5, 2024 / Bronstein
...more
(280)
•••
whytestocks
X
Post by
whytestocks
on Aug 29, 2024 1:45pm
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharma
Just In: $SYRS Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities InvestigationNEW YORK CITY, NY / ACCESSWIRE / August 29, 2024
...more
(280)
•••
whytestocks
X
Post by
whytestocks
on Aug 28, 2024 2:02pm
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein,
NEWS: $SYRS Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsNEW YORK CITY, NY / ACCESSWIRE
...more
(280)
•••
whytestocks
X
Post by
whytestocks
on Aug 26, 2024 3:32pm
Bronstein, Gewirtz and Grossman, LLC Announces an Investigat
BREAKING NEWS: $SYRS Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Investors to Seek Compensation for Alleged WrongdoingsNEW
...more
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 10:55am
Syros (NASDAQ:SYRS) Poised for Potential Breakthrough in Hem
https://beyondspx.com/2024/07/31/syros-nasdaqsyrs-poised-for-potential-breakthrough-in-hematologic-malignancies/
(280)
•••
whytestocks
X
Post by
whytestocks
on Jun 13, 2024 2:30pm
Syros to Host Webcast Event on Higher-Risk Myelodysplastic S
News; $SYRS Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments